Abstract: Amorphous methyl((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate free base, amorphous methyl((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate dihydrochloride, methods of making them, and pharmaceutical compositions containing them.

Abstract: The present invention relates to an environmentally friendly process for preparing rivaroxaban. The present invention provides a process for preparing rivaroxaban of formula I, the process comprising: reacting a compound of formula VI with a base in the presence of a solvent to form a compound of formula VII; and condensing the compound of formula VII with a compound of formula VIII or a compound of formula IX in the presence of a solvent to prepare rivaroxaban of formula I, wherein the solvent used in both steps comprises water.

Abstract: The present invention discloses a novel process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts thereof and to novel intermediates which are produced during the course of carrying out the novel process.

Abstract: The present invention relates to a novel process for the synthesis of everolimus of formula (I): and intermediates thereof.

Abstract: The present invention relates to an efficient process for the separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine and to a process for preparing 9-[(R)-2-[[(R)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine and 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine.

Abstract: An aspect of the present invention provides for capturing of audit trail data related to processing of requests. In an embodiment, the received requests are classified into a first category and a second category. For each request in the first category, the corresponding audit trail data is stored directly into non-volatile storage upon processing of the request. On the other hand, for each request in the second category, the audit trail data is first stored into a volatile memory upon processing of the request, and then later copied from the volatile memory to non-volatile storage. Thus, the audit trail data corresponding to both categories of requests is eventually available stored on non-volatile storage.

Abstract: In view of the foregoing, an embodiment herein provides a method of manufacturing wheel disc, wherein said method comprising of steps providing a rectangular strip made of metallic materials, circling the strip to form a band, welding the band to form a hoop by welding process, forming one side of the hoop to make the center portion of the disc, spinning another side of the hoop to form flange of the disc, and achieving varying thickness across the disc to make variable thickness wherever needed, thereby reducing the usage of raw material and reducing wastage and making light weight wheel disc.

Abstract: The present invention provides improved processes for the preparation of Bortezomib, tert -butyl[1-({(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-1-oxo-3-phenylpropan-2-yl]carbamate of formula (IV) and N-{(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl} phenylalanine of formula (V). Compound (IV) is prepared by coupling (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethyl-hexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butan-1-amine of formula (II) or its salt with N-(tert-butoxycarbonyl)-L -phenylalanine of formula (III) in a first solvent in the presence of a first coupling agent and a first base, wherein the coupling process does not comprise solvent exchange. Compound (V) is prepared by deprotecting compound (IV) using an alcoholic solution of an inorganic acid.

Abstract: A device is configured to store information indicating a threshold bandwidth with which a multi-lane link is permitted to operate. The device may establish the multi-lane link with a peer device. The multi-lane link may include multiple lanes used to communicate data with the peer device. The device may determine fault states for the lanes included in the multi-lane link. A fault state, for a particular lane, may indicate that the particular lane is faulty. The device may determine an available bandwidth for the multi-lane link based on the fault states for the lanes. The device may selectively terminate the multi-lane link or operate the multi-lane link at the available bandwidth based on whether the available bandwidth satisfies the threshold bandwidth.

Abstract: Methods for fabricating a piezoelectric device are provided. The methods can include providing a substrate and forming a nanocrystalline diamond layer on a first surface of the substrate. The methods can also include depositing a piezoelectric layer on a first surface of the nanocrystalline diamond layer.

Abstract: A device is configured to store information indicating a threshold bandwidth with which a multi-lane link is permitted to operate. The device may establish the multi-lane link with a peer device. The multi-lane link may include multiple lanes used to communicate data with the peer device. The device may determine fault states for the lanes included in the multi-lane link. A fault state, for a particular lane, may indicate that the particular lane is faulty. The device may determine an available bandwidth for the multi-lane link based on the fault states for the lanes. The device may selectively terminate the multi-lane link or operate the multi-lane link at the available bandwidth based on whether the available bandwidth satisfies the threshold bandwidth.

Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Abstract: Convenient approach for managing records with respect to entities based on file plans. In an embodiment, historical data representing policies previously selected is maintained. The historical data is then used to generate custom file plans containing policies most likely to be used by a corresponding user. A list in such custom file plan may have more relevant policies prioritized higher. A user may thus conveniently select a desired policy, and associate the selected policy with a set of entities to cause the selected policies to be applied against management of the set of entities.

Abstract: Various aspects of a method and system for digital rights management of encrypted digital content are disclosed herein. The method includes determination of a seed value from a pre-stored vault file that corresponds to a registered user. The determination of the seed value is based on biometric information provided by the registered user. The method further includes generation of a set of intermediate values based on the determined seed value. The generation of the set of intermediate values is based on a pre-determined rule. The method further includes determination of a content key based on the generated set of intermediate values.

Abstract: Methods for fabricating a piezoelectric device are provided. The methods can include providing a substrate and forming a nanocrystalline diamond layer on a first surface of the substrate. The methods can also include depositing a piezoelectric layer on a first surface of the nanocrystalline diamond layer.

Abstract: The present invention relates to an efficient process for the separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine and to a process for preparing 9-[(R)-2-[[(R)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine and 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine.

Abstract: In one aspect, methods relate to the field of recombinant DNA therapeutics. Methods may involve bio-informatics design, synthesis of artificial genes for a human insulin precursor having a leader peptide coding sequence, cloning artificial genes into an expression vector, and expression in an organism such as one selected from the genus Pichia. In another aspect, methods may include downstream processing for obtaining protein precursor molecules and subsequent conversion of protein precursor molecules to functional proteins.

Abstract: A novel and improved process for preparation of bortezomib mannitol ester is derived, which process avoids excessive use of solvents, involves convenient, industrially feasible and economical techniques, and provides improvements in purity over processes known in the art.

Abstract: In one aspect, methods relate to the field of recombinant DNA therapeutics. Methods may involve bio-informatics design, synthesis of artificial genes for a human insulin precursor having a leader peptide coding sequence, cloning artificial genes into an expression vector, and expression in an organism such as one selected from the genus Pichia. In another aspect, methods may include downstream processing for obtaining protein precursor molecules and subsequent conversion of protein precursor molecules to functional proteins.

Abstract: There is provided a process for the preparation of sitagliptin or a pharmaceutically acceptable salt thereof, and a process for the preparation of intermediate compounds useful in the preparation of sitagliptin. In particular, there is provided a process comprising condensing 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butyric acid of formula (II) with 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine of formula (III) or a salt thereof in presence of a catalyst to obtain (R)-tert-butyl-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl-carbamate of formula (IV) or a pharmaceutically acceptable salt thereof. The catalyst is represented by the compound of formula (V). Compound of formula (IV) or its pharmaceutically acceptable salt obtained may be deprotected to obtain a compound of formula (I).